The president’s team has mobilized to counter the downgrade of Treasury debt by the Fitch Ratings agency, rushing to defend the story of an improving economic outlook.
Category: Medicare
-
Drugmakers Throw ‘Kitchen Sink’ to Halt Medicare Price Negotiations
The government will soon announce the first 10 medications that will be subject to price negotiations with Medicare under a new law. Drugmakers are fighting the measure in court.
-
Profiting From Risky Atherectomies That Can Lead to Amputations
Medical device makers have bankrolled a cottage industry of doctors and clinics that perform artery-clearing procedures that can lead to amputations.
-
What to Know About Leqembi, the Alzheimer’s Drug Approved by the FDA
Medicare will cover much of the cost for patients in the early stages of the disease, but Leqembi has safety risks and can only modestly slow cognitive decline.
-
FDA Makes Alzheimer’s Drug Leqembi Widely Accessible
The F.D.A. gave full approval to the drug, but added a black-box warning about safety risks. Medicare said it would cover most of the high cost.
-
Retiree Medical Costs Expected to Stay Flat in 2023
An estimate puts the average cost over a 20-year retirement at about $157,000. That’s almost double the estimate in 2002.
-
States Try Easing the Burden of Long-Term Care’s High Cost
Seeing their own financial benefits, too, Washington and California are among the states creating programs to help older residents.
-
Hospice Is a Profitable Business, but Nonprofits Mostly Do a Better Job
Nearly three-quarters of hospice organizations are now for-profit. Complaints of fraud and profiteering are growing.
-
Merck Sues Over Medicare Drug-Price Negotiation Law
The company is heavily reliant on a cancer drug that could be targeted by a program intended to lower drug prices.